The trial has been approved by UK regulators and ethical reviewers and interested candidates will have to volunteer for the programme.
The vaccine, the university said, is based on an adenovirus vaccine vector and the SARS COV-2 spike protein is already in production but won't be ready for some weeks still.
"The team will enrol healthy volunteers aged between 18-55, who, if they pass screening, will be the first humans to test the new vaccine, called ChAdOx1 nCoV-19," the varsity said in a statement.
The trial will provide valuable information on the safety aspects of the vaccine, as well as its ability to generate an immune response against the virus.
The trial collaboration between the University's Jenner Institute and Oxford Vaccine Group clinical teams will recruit up to 510 volunteers.
They will receive either the CHADOX1 nCoV 19 vaccine or a control injection for comparison
"While the team will start screening people now to see if they are eligible to take part in the study participants will not receive the vaccine for some weeks," the statement added.
